Introduction
============

Restenosis, a major complication leading to recurrent acute coronary diseases and even death ([@b4-gmb-34-1-25]), occurs in 30%--40% of the patients following percutaneous transluminal coronary angioplasty (PTCA). To date, the underlying mechanisms are not yet completely understood, even though several etiological factors have already been identified, these including the proliferation and migration of VSMCs, platelet adherence and aggregation, thrombus formation, the infiltration of inflammatory cells, as well as vascular remodeling ([@b6-gmb-34-1-25]; [@b13-gmb-34-1-25]; [@b24-gmb-34-1-25]).

The tissue factor (TF) is a key initiator of the coagulation cascade ([@b3-gmb-34-1-25]). It also participates in other cellular processes including migration and proliferation of VSMCs ([@b5-gmb-34-1-25]). It has been shown to mediate a prolonged prothrombotic state after balloon angioplasty, by generating active serine proteases of the coagulation cascade, these including factor VIIa (VIIa), factor Xa, and thrombin ([@b5-gmb-34-1-25]). These proteases promote the development of restenosis by both thrombotic and non-thrombotic mechanisms, exerting mitogenic and chemotactic effects on VSMCs and by eliciting a proinflammatory response ([@b18-gmb-34-1-25]; [@b27-gmb-34-1-25]). Hence, the possibility of blocking TF activity could lead to a reduction in thrombosis, local inflammation, and the proliferation and migration of VSMCs, and, consequently, intimal hyperplasia in injured blood vessels.

The tissue factor pathway inhibitor (TFPI), a Kunitz-type protease inhibitor, exerts feedback inhibition on the TF/VIIa-complex in an Xa-dependent manner ([@b1-gmb-34-1-25]). It has been attracting increasing research effort as a potential agent for curing restenosis, since it was found to attenuate thrombus formation ([@b21-gmb-34-1-25]), reduce local inflammatory responses induced by injury to blood vessels, and suppress the proliferation and migration of VSMCs ([@b14-gmb-34-1-25]). Research, based on animal models, has amply confirmed that TFPI, in the form of either recombinant protein or gene, reduce restenosis induced by blood vessel injury ([@b9-gmb-34-1-25]; [@b10-gmb-34-1-25]; [@b25-gmb-34-1-25], [@b26-gmb-34-1-25]; [@b28-gmb-34-1-25]). Since VSMCs proliferation and migration plays a central role in the progression of neointimal hyperplasia, it is of particular interest to understand the mechanism through which TFPIs modulate the former of the two.

Apoptosis induction is one of the major strategies for reducing cell proliferation. Recent investigation using animal models has revealed that adenovirus-mediated TFPI gene transfer induced apoptosis in VSMCs through the intrinsic pathway ([@b7-gmb-34-1-25]), adding more evidence to a deeper understanding of the mechanisms underlying its anti-proliferative behavior. Even so, little is known regarding the impact of the TFPI gene on hVSMCs.

The current study was designed to investigate whether TFPI could induce also apoptosis in hVSMCs, as well as the underlying mechanisms involved. We could show that TFPI over-expression in human VSMCs induced cellular apoptosis through both intrinsic and extrinsic apoptotic pathways.

Materials and Methods
=====================

Isolation and identification of VSMCs
-------------------------------------

hVSMCs were isolated from human umbilical artery according to the method described by [@b19-gmb-34-1-25]. Briefly, 3--5 cm sections of arteries isolated from the human umbilical cord were perfused with a physiological saline solution to remove the remaining internal blood. This was done by means of a 20 mL syringe connected to a needle. After cutting open and gently scraping off the intima, the blood vessels were sectioned into even smaller pieces of 2--3 mm^3^, for culture in 25 cm^2^ flasks, with DMEM supplemented with 10% fetal-calf serum (FBS) and 10% human AB serum. Culture itself was by incubation in a humidified 5% CO~2~ incubator at 37 °C. The medium was refreshed every 3 days until the cells reached about 90% confluence. Purification of hVSMCs was carried out by differential attachment, the cells of passage 3 being used for further investigation. The isolated hVSMCs were identified by immunocytochemical staining, using monoclonal antibodies against smooth muscle actin-α, according to manufacturer's instructions, with a non-specific serum as antibody control.

Construction of the TFPI encoding plasmid
-----------------------------------------

In order to construct a recombinant plasmid expressing TFPI in eukaryotic cells, TFPI cDNA, a generous gift from Professor George J. Broze Jr. at Washington University School of Medicine, was inserted into the pIRES 1-neo plasmid by using standard DNA recombination techniques. The resulting plasmid pIRES-TFPI was confirmed by DNA sequencing.

Detection of TFPI expression in VSMCs by RT-PCR
-----------------------------------------------

hVSMCs were seeded into 25 cm^2^ flasks and incubated overnight at 37 °C in a humidified 5% CO~2~ incubator. Thereafter, the cells were divided into 3 groups (8 flasks/group) and treated with pIRES-TFPI plasmid (2 μg/mL), pIRES 1-neo plasmid (2 μg/mL) and fresh medium, respectively, using lipofectamine as transfection reagent according to manufacturer's instructions. Total RNA was extracted with Trizol reagent 3 days after transfection, and subsequently amplified by RT-PCR with TFPI specific primers (5′-GGAAGAAGATCCTGGAATATGTCGAGG -3′, and 5′-CTTGGTTGATTGCGGAGTCAGGGAG-3′). GAPDH was amplified as internal control, using the following primers: 5′-ACCACAGTCCATGCCATCACT-3′ and 5′-TCCACACCCTGTTGCTGTA-3′. The amplified DNA was analyzed through electrophoresis followed by optical density scanning using a GDS8000 Gel Documentation and Analysis System (Cambridge, UK).

Testing of cell viability by MTT assay
--------------------------------------

hVSMCs were seeded into a 96-well plate and incubated overnight at 37 °C in a humidified 5% CO~2~ incubator. The cells were divided into 3 groups (8 wells/group) and treated with pIRES-TFPI plasmid (2 μg/mL), pIRES 1-neo plasmid (2 μg/mL) and fresh medium, respectively, using lipofectamine as transfection reagent according to manufacturer's instructions. Cell viability was measured 3, 5 and 7 days after DNA transfection by MTT assay as described previously ([@b20-gmb-34-1-25]). The test was repeated twice.

Measurement of cell proliferation
---------------------------------

hVSMCs were seeded into a 48-well plate and incubated at 37 °C in a humidified 5% CO~2~ incubator. Cells were divided into three groups, and treated with pIRES-TFPI plasmid (2 μg/mL), pIRES 1-neo plasmid (2 μg/mL) and fresh medium, respectively, using lipofectamine as transfection reagent, according to manufacturer's instructions. The cells were counted using a cytometer from 2 to 7 days after DNA transfection. The experiment was repeated twice.

Flow-cytometry for cell apoptosis analysis
------------------------------------------

hVSMCs were seeded into 25 cm^2^ flasks and incubated overnight at 37 °C in a humidified 5% CO~2~ incubator. The cells, divided into three groups, were treated with pIRES-TFPI plasmid (2 μg /mL), pIRES 1-neo plasmid and fresh medium, respectively, using lipofectamine as transfection reagent, according to manufacturer's instructions. Harvesting was done 5 and 7 days after transfection. Cells were first washed with PBS and counted, and then suspended in a 1x binding buffer at a density of 1 x 10^6^ cells/mL. After transfer to a 5 mL culture tube, 100 μL of the cell suspension (1 x 10^5^ cells) was transferred to a 5 mL culture tube and then gently mixed with 5 μL of FITC-Annexin V and 10 μL of PI solution. After a 15 min's incubation in the dark at RT, 400 μL of 1x binding buffer was added to each tube, followed by FACS analysis (NJ, USA). The experiment was repeated twice.

Western blotting
----------------

Western blotting was performed to verify the amount of the proteins involved in apoptosis. In brief, 5 days after DNA transfection, the cells were harvested, washed with PBS, and resuspended in cold lysis buffer containing PMSF (1 mM). The cell lysates were subsequently incubated on ice for 30 min and centrifuged at 12,000 *g* for 10 min at 4 °C. The amount of protein was determined using a Bradford protein-assay kit. Aliquots of the cell lysates containing 50 μg of proteins were mixed with SDS-sample buffers and subjected to electrophoresis on 10% PAGE gels followed by routine Western blotting analysis using antibodies against procaspase-8, procaspase-9, procaspase-3, cyt-c, and β-actin (Santa Cruz, USA). The experiment was repeated three times and the results were presented as mean values of the three tests.

Statistical analysis
--------------------

Statistical analysis was performed using one way ANOVA (one-way analysis of variance) followed by Bonferroni t-tests for comparisons with the control group. The values were presented as means ± SD of eight tests, and statistical significance was determined at p \< 0.05.

Results
=======

TFPI gene transfer led to elevated TFPI expression in hVSMCs
------------------------------------------------------------

TFPI mRNA levels in hVSMCs were determined by RT-PCR, with simultaneously amplified GAPDH, as internal control. As shown in [Figure 1A](#f1-gmb-34-1-25){ref-type="fig"}, a DNA fragment of around 230 bps was amplified by TFPI specific primers and a DNA fragment of around 500 bps by GAPDH specific primers. [Figure 1B](#f1-gmb-34-1-25){ref-type="fig"} shows that the TFPI/ GAPDH ratio in cells treated with pIRES-TFPI (1.50) was significantly higher than in those treated with pIRES 1-neo (0.70) or normal ones (0.60). The fact of there being no significant difference in treatment between the pIRES 1-neo treated cells and normal cells indicates that TFPI gene transfer did, in fact, result in higher expression of TFPI.

Suppressed cell viability and proliferation as a result of TFPI gene transfer
-----------------------------------------------------------------------------

Both MTT assay and cell counting demonstrated that pIRES-TFPI gene transfer resulted in decreased cell viability and proliferation, in a time dependent manner, compared with pIRES 1-neo plasmid treatment, thereby inferring the inhibitory effect of the TFPI gene on VSMCs proliferation ([Figure 2](#f2-gmb-34-1-25){ref-type="fig"}).

TFPI gene induced cell apoptosis in hVSMCs
------------------------------------------

The results obtained demonstrated that TFPI gene transfer started to reveal its inhibitory effect on VSMC proliferation from the 5^th^ day after DNA transfection ([Figure 2](#f2-gmb-34-1-25){ref-type="fig"}). Thus, the 5^th^ and 7^th^ days post-transfection were chosen for observing the impact of TFPI gene transfer on cellular apoptosis. We found that the TFPI gene induced significantly higher cellular apoptosis in comparison to experimental controls ([Figure 3](#f3-gmb-34-1-25){ref-type="fig"}). To further explore the underlying mechanisms, certain key proteins involved in apoptosis were analyzed through Western blotting, showing that TFPI gene transfer led to decreased expression of procaspase-3, procaspase-8 and procascase-9, and increased release of cyt-c into the cytoplasm in comparison to the control groups ([Figure 4](#f4-gmb-34-1-25){ref-type="fig"}).

Discussion
==========

Both the abnormal proliferation and migration of VSMCs contribute significantly to restenosis progression after cardiovascular intervention such as PTCA, which leads to high long-term failure rates of bypass surgery and angioplasty in the treatment of cardiovascular diseases. Therefore, the development of molecular strategies that effectively block such pathogenic cellular processes has been the focus of much research and many clinical trials over the past two decades ([@b15-gmb-34-1-25], [@b16-gmb-34-1-25]).

VSMCs usually comprise two phenotypes, namely contractile and synthetic. The contractile phenotype cells are spindle-shaped with low frequency of proliferation, whereas the synthetic phenotype cells are rhomboid-shaped showing a high degree of protein synthesis, proliferation and migratory activity. It is generally agreed that contractile differentiated VSMCs are the typical phenotype of the vascular wall under most normal, physiological conditions, whereas synthetic dedifferentiated VSMCs only exist during developmental and pathological processes. In response to various stimuli including vascular injury, VSMCs switch from the quiescent contractile phenotype to the synthetic one, proliferate in media, and migrate from the media to the intima, where they undergo further proliferation leading to neointimal hyperplasia. Reduction of neointimal hyperplasia could be achieved either by regulating the cell cycle (cytostatic strategy), or by inducing cell-death, such as apoptosis (cytotoxic strategy).

Apoptosis normally occurs during development and aging, as a homeostatic mechanism to maintain cell populations in tissues. It also operates as a defense mechanism against cell-damage induced by diseases or noxious agents ([@b22-gmb-34-1-25]). The highly complex and sophisticated apoptosis mechanisms involve a cascade of molecular events. It is generally agreed that there are two major apoptotic pathways, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway. Recent evidence demonstrates that the two pathways are linked and converge on the execution pathway ([@b12-gmb-34-1-25]). The extrinsic pathway involves the binding of ligands to their corresponding death receptors, followed by a series of molecular events leading to auto-catalytic activation of procaspase-8 ([@b17-gmb-34-1-25]). In the intrinsic pathway, apoptosis is triggered by a varied array of intracellular signals that act directly on targets within the cell. All these signals induce changes in the inner mitochondrial membrane, thereby leading to opening of the mitochondrial permeability transition pore, loss of mitochondrial transmembrane potential, and the release of pro-apoptotic proteins, such as cyt-c, from intermembrane space into the cytosol ([@b23-gmb-34-1-25]). Cyt-c binds to and activates Apaf-1, as well as procaspase-9, thereby leading to caspase-9 activation ([@b2-gmb-34-1-25]; [@b11-gmb-34-1-25]). Both pathways end at the execution phase. Caspase-3, considered to be the most important of the executioner caspases, is activated by any one of the initiator caspases including caspase-8 and caspase-9.

As demonstrated in the current study, TFPI gene transfer could suppress the proliferation of neonatal VSMCs from human umbilical artery that share characteristics similar to those of synthetic VSMCs observed in restenosis lesions ([@b8-gmb-34-1-25]). This is in line with a previous report showing TFPI gene-induced apoptosis in rat VSMCs by ([@b7-gmb-34-1-25]). Nevertheless, the current study showed that TFPI gene transfer reduced the expression of caspase 3, caspase 8, and caspase 9 and induced the release of cyt-c into the cytosol. This implies the involvement of both extrinsic and intrinsic pathways in TFPI gene-induced cellular apoptosis, contrary to that observed in rats, where only the intrinsic pathway was affected ([@b7-gmb-34-1-25]). The mechanisms underlying the difference in impact of the TFPI gene on apoptotic pathways needs to be further elucidated.
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![Analysis of RT-PCR amplification of TFPI by agarose gel electrophoresis. (A) M: DNA maker; 1: TFPI amplification in the non-transfection group; 2: TFPI amplification in pIRES 1-neo group; 3: TFPI amplification in the pIRES-TFPI group; 4: GAPDH amplification in the non-transfection group; 5: GAPDH amplification in the pIRES 1-neo group; 6: GAPDH amplification in the pIRES-TFPI group. (B) TFPI mRNA levels standardized by GAPDH. ^\*^p \< 0.05 as compared to the pIRES 1-neo or non-transfection group (n = 8).](gmb-34-1-25-gfig1){#f1-gmb-34-1-25}

![Cell viability measured by MTT. (A) Cell proliferation measured by cell counting. B ^\*^p \< 0.05 as compared with the pIRES 1-neo group (n = 16); ^Δ^p \< 0.05 as compared with the non-transfection group (n = 16).](gmb-34-1-25-gfig2){#f2-gmb-34-1-25}

![Cell apoptosis analysis at the 5^th^ (A) and 7^th^ (B) days after gene transfection. ^\*^p \< 0.05 in comparison to the pIRES 1-neo group or the non-transfection group (n = 8).](gmb-34-1-25-gfig3){#f3-gmb-34-1-25}

![Western blot analysis for procaspase-8, procaspase-9, procaspase-3, and cyt-c. (A) Representative data of Western blotting for pIRES-TFPI treated group (a), pIRES 1-neo treated group (b) and non-transfection group (c); (B) protein levels standardized by β-actin. ^\*^p \< 0.05 as compared with the pIRES 1-neo group (n = 3).](gmb-34-1-25-gfig4){#f4-gmb-34-1-25}
